Showing presentation: reset
BET-bromodomain inhibitor OTX015 shows clinically meaningful activity at nontoxic doses: interim results of an ongoing phase I trial in hematologic malignancies
- Sort by:
- Browse by:
- Free
- slides video
- audio + slides
- All slides included
BET-bromodomain inhibitor OTX015 shows clinically meaningful activity at nontoxic doses: interim results of an ongoing phase I trial in hematologic malignancies
Esteban Cvitkovic
Oncoethix SA, Lausanne, Switzerland